Sage Rhino Capital LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 666 shares of the medical research company’s stock, valued at approximately $241,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Laurel Wealth Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 104.3% during the first quarter. Laurel Wealth Advisors LLC now owns 94 shares of the medical research company’s stock worth $27,000 after purchasing an additional 48 shares during the last quarter. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in shares of Thermo Fisher Scientific during the first quarter worth $28,000. Ballast Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the first quarter worth $35,000. Investors Research Corp raised its holdings in shares of Thermo Fisher Scientific by 100.0% during the second quarter. Investors Research Corp now owns 120 shares of the medical research company’s stock worth $39,000 after purchasing an additional 60 shares during the last quarter. Finally, Liberty One Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth $41,000. 87.51% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE TMO traded up $3.39 during trading on Friday, hitting $413.95. The company had a trading volume of 1,217,905 shares, compared to its average volume of 1,232,426. The stock has a fifty day simple moving average of $373.97 and a two-hundred day simple moving average of $335.37. Thermo Fisher Scientific Inc. has a fifty-two week low of $250.21 and a fifty-two week high of $420.99. The firm has a market capitalization of $163.49 billion, a price-to-earnings ratio of 44.80, a price-to-earnings-growth ratio of 1.85 and a beta of 1.04. The company has a quick ratio of 2.02, a current ratio of 2.62 and a debt-to-equity ratio of 0.69.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 22nd. The medical research company reported $3.89 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.22. Thermo Fisher Scientific had a net margin of 14.12% and a return on equity of 18.18%. The business had revenue of $6.92 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the business earned $3.04 earnings per share. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 14.95 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.22 dividend. The ex-dividend date of this dividend is Monday, September 14th. This represents a $0.88 annualized dividend and a dividend yield of 0.21%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.13%.

TMO has been the subject of several recent research reports. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Wednesday, July 15th. Stifel Nicolaus raised their price target on shares of Thermo Fisher Scientific from $370.00 to $460.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. Needham & Company LLC raised their price target on shares of Thermo Fisher Scientific from $415.00 to $468.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. Citigroup raised their price target on shares of Thermo Fisher Scientific from $390.00 to $471.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. Finally, Robert W. Baird raised their price target on shares of Thermo Fisher Scientific from $352.00 to $436.00 in a research report on Thursday, July 23rd. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $420.50.

In other news, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $348.00, for a total value of $870,000.00. Following the transaction, the chief financial officer now directly owns 37,989 shares of the company’s stock, valued at $13,220,172. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $411.05, for a total transaction of $8,221,000.00. Following the completion of the transaction, the chief executive officer now directly owns 260,446 shares in the company, valued at $107,056,328.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 171,031 shares of company stock worth $67,284,857. Insiders own 0.44% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Back-End Load

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.